Author Index to Volume 48

Abi-Dargham A. See Kegeles LS
Ablon JS. See Cohen LS
Abraham G. See David MM
Adès J. See Gorwood P
Aggen SH. See Young EA
Akamatsu T. See Shibui K
Akil H. See Watson SJ
Ali M. See Mangold D
Alila-Johansson A. See Lindblom N
Alpert NM. See Heckers S
Alpert NM. See Shin LM
Altemus M. See Frank GK
Altshuler L. See Rush AJ
Altshuler LL, Bartzokis G, Grieder T, Curran J, Jimenez T, Leight K, Wilkins J, Gerner R, Mintz J. An MRI study of temporal lobe structures in men with bipolar disorder or schizophrenia, 147
Ancoli-Israel S. See Bardwell WA
Andreasen NC. See Crespo-Facorro B
Andreasen NC. See Sears LL
Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder, 445
Arana GW. See George MS
Arciniegas D. See Teale P
Arndt S. See Strakowski SM
Arsenault NJ. See Woodward SH
Austin MC. See Glantz LA
Axelson DA. See Dahl RE
Axelson DA. See De Bellis MD

Bailey JW. See Cohen LS
Bakshi VP, Kalin NH. Corticotropin-releasing hormone and animal models of anxiety: gene–environment interactions, 1175
Baldessarini RJ. See Tohen M
Ballenger JC. See George MS
Bardwell WA, Moore P, Ancoli-Israel S, Dimsdale JE. Does obstructive sleep apnea confound sleep architecture findings in subjects with depressive symptoms?, 1001
Barrio JR. See MacLaren DC
Bartzokis G. See Altshuler LL
Baştürk M. See Turan MT
Batel P. See Gorwood P
Battaglia M, Ogliari A, Maffei C, Marino C, Molteni M, Nobile M. Cautionary note: complex (dys)function of the serotonin transporter, 334-corr
Baucom C. See Miguel-Hidalgo JJ
Bayles-Dazet W. See Winokur A
Beardslee WR. See Steingard RJ
Bebchuk JM. See Moore GJ
Begleiter H. See Hada M
Beiser M. See Sponheim SR
Bellivier F, Szöke A, Henry C, Lacoste J, Bottos C, Nosten-Bertrand M, Hardy P, Rouillon F, Launay J-M, Laplanche J-L, Leboyer M. Possible association between serotonin transporter gene polymorphism and violent suicidal behavior in mood disorders, 319
Benazon NR. See Rosenberg DR
Benson BE. See Osuch EA
Benson ES. See Manoach DS
Berga SL. See Moses EL
Berrettini WH. Are schizophrenic and bipolar disorders related? A review of family and molecular studies, 531
Biederman J. See Faraone SV
Biederman J, Faraone SV, Wozniak J, Monuteaux MC. Parsing the association between bipolar, conduct, and substance use disorders: a familial risk analysis, 1037
Biederman J, Mick E, Faraone SV, Spencer T, Wilens TE, Wozniak J. Pediatric mania: a developmental subtype of bipolar disorder?, 458
Bienvenu OJ, Samuels JF, Riddle MA, Hoehn-Saric R, Liang K-Y, Cullen BAM, Grados MA, Nestadt G. The relationship of obsessive–compulsive disorder to possible spectrum disorders: results from a family study, 287
Bilker W. See Kohler CG
Birmaher B. See Dahl RE
Birmaher B. See De Bellis MD
Bish JA. See Gold JM
Blitchington TF. See Steffens DC
Bliwise DL. See Woodward SH
Blumberg HP, Stern E, Martinez D, Ricketts S, de Asis J, White T, Epstein J, McBride PA, Eidelberg D, Kocsis JH, Silbersweig DA. Increased anterior cingulate and caudate activity in bipolar mania, 1045
Boni C. See Gorwood P
Boring AM. See De Bellis MD
Bottos C. See Bellivier F
Bouffard SM. See Cohen LS
Bouhuys AL. See Flentge F
Brannan SK. See Liotti M
Brannan SK. See Mayberg HS
Bravi D. See Sacchetti E
Brent DA. See Dahl RE
Breslau N, Davis GC, Peterson EL, Schultz LR. A second look at comorbidity in victims of trauma: the posttraumatic stress disorder–major depression connection, 902
Brodkin K. See Pascualy M
Broft A. See Martinez D
Bromet EJ. See Neria Y
Brooke SM, Sapolsky RM. The effects of steroid hromones in HIV-related neurotoxicity: a mini review, 881
Brunner D. See Gross C
Buchanan RW. See Gold JM
Buppanharun W. See Chanpattana W
Butters MA. See Moses EL
Byrum CE. See Lai T-J
Byrum CE. See Steffens DC

Caldji C, Diorio J, Meaney MJ. Variations in maternal care in infancy regulate the development of stress reactivity, 1164
Campbell IG. See Tan X
Candemir Z. See Turan MT
Carlsson A. See Kegeles LS
Casey BJ. See De Bellis MD
Chakrabhand MLS. See Chanpattana W
Chanpattana W, Chakrabhand MLS, Buppanharun W, Sackeim HA. Effects of stimulus intensity on the efficacy of bilateral ECT in

Abbreviations:
ed, editorial
corr, correspondence

© 2000 Society of Biological Psychiatry

0006-3223/00/$20.00
PII S0006-3223(00)01103-3

schizophrenia: a preliminary study, 222
Charney DS. See Fujita M
Charney DS. See Kaufman J
Charney DS. Bipolar disorder: can studies of natural history help us define clinically and neurobiologically relevant subtypes?, 427-ed
Chen B, Wang JF, Young LT. Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus, 658
Chen G. See Manji HK
Chen G. See Moore GJ
Cherry SR. See MacLaren DC
Christensen JD, Kaufman MJ, Frederick BdeB, Rose SL, Moore CM, Lukas SE, Mendelson JH, Cohen BM, Renshaw PF. Proton magnetic resonance spectroscopy of human basal ganglia: response to cocaine administration, 685
Clementz BA. See Sponheim SR
Clopton P. See Parry BL
Cohen BM. See Christensen JD
Cohen BM. See Stoll AL
Cohen BM. See Tohen M
Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fluoxetine, 996
Comazzi M. See DeLisi LE
Cooke R. See Emamghoreishi M
Cooper TB. See Kegeles LS
Copolov DL. See Crook JM
Crespo-Facorro B, Kim J-J, Andreasen NC, O'Leary DS, Magnotta V. Regional frontal abnormalities in schizophrenia: a quantitative gray matter volume and cortical surface size study, 110
Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation, 381
Crow TJ. See DeLisi LE
Cullen BAM. See Bienvenu OJ
Culler M. See Goldstein G
Curran J. See Altshuler LL
Curran T. See Heckers S

Dahl RE. See De Bellis MD
Dahl RE, Birmaher B, Williamson DE, Dorn L, Perel J, Kaufman J, Brent DA, Axelson DA. Ryan ND. Low growth hormone response to growth hormone–releasing hormone in child depression, 981
Danker-Hopfe H. See Kraemer S
David MM, Owen JA, Abraham G, Delva NJ, Southmayd SE, Wooltorton E, Lawson JS. Thyroid function and response to 48-hour sleep deprivation in treatment-resistant depressed patients, 323
Davis GC. See Breslau N
Davis KL. See Sokolov BP
Dawson R. See Lavori PW
Dean B. See Crook JM
de Asis J. See Blumberg HP
De Bellis MD, Casey BJ, Dahl RE, Birmaher B, Williamson DE, Thomas KM, Axelson DA, Frustaci K, Boring AM, Hall J, Ryan ND. A pilot study of amygdala volumes in pediatric generalized anxiety disorder, 51
Delahanty DL, Raimonde AJ, Spoonster E. Initial posttraumatic urinary cortisol levels predict subsequent PTSD symptoms in motor vehicle accident victims, 940
DelBello MP. See Strakowski SM
Delgado PL. See Moreno FA
DeLisi LE. See Gharaibeh WS
DeLisi LE, Razi K, Stewart J, Relja M, Shields G, Smith AB, Wellman N, Larach VW, Loftus J, Vita A, Comazzi M, Crow TJ. No evidence for a parent-of-origin effect detected in the pattern of inheritance of schizophrenia, 706
Delva NJ. See David MM
Dickey CC. See Niznikiewicz MA
Dilley G. See Miguel-Hidalgo JJ
Dilley G. See Piletz JE
Dimsdale JE. See Bardwell WA
Diorio J. See Caldji C
Dorn H. See Kraemer S
Dorn L. See Dahl RE
Dougherty DD. See Shin LM
Doyle AE. See Faraone SV
Drevets WC. See Moses EL
Drevets WC. Neuroimaging studies of mood disorders, 813
D'Sa C. See Duman RS
Duman RS, Malberg J, Nakagawa S, D'Sa C. Neuronal plasticity and survival in mood disorders, 732
Dündar M. See Turan MT
Ehlert I. See Kraemer S
Eidelberg D. See Blumberg HP
Emamghoreishi M, Li PP, Schlichter L, Parikh SV, Cooke R, Warsh JJ. Associated disturbances in calcium homeostasis and G protein–mediated cAMP signaling in bipolar I disorder, 665
Epstein J. See Blumberg HP
Eşel E. See Turan MT
Exton MS. See Meyer G

Faedda GL. See Tohen M
Faraone SV. See Biederman J
Faraone SV. See Fucetola R
Faraone SV. See Tsuang MT
Faraone SV, Biederman J, Monuteaux MC. Attention-deficit disorder and conduct disorder in girls: evidence for a familial subtype, 21
Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E, Doyle AE. Attention-deficit/hyperactivity disorder in adults: an overview, 9
Faraone SV, Seidman LJ, Kremen WS, Toomey R, Pepple JR, Tsuang MT. Neuropsychologic functioning among the nonpsychotic relatives of schizophrenic patients: the effect of genetic loading, 120
Faulk MW. See Moore GJ
Fava M. See Goldstein G
Feinberg I. See Tan X
Fischman AJ. See Heckers S
Fischman AJ. See Shin LM
Fisher A. See Goldstein G
Fleck DE. See Strakowski SM
Flentge F, van den Berg MD, Bouhuys AL, The HT. Increase of NK–T cells in aged depressed patients not treated with antidepressive drugs, 1024
Fox PT. See Liotti M
Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder, 593
Frank GK, Kaye WH, Altemus M, Greeno CG. CSF oxytocin and vasopressin levels after recovery from bulimia nervosa and anorexia nervosa, bulimic subtype, 315
Frederick BdeB. See Christensen JD
Freed WJ. See Vawter MP
Frustaci K. See De Bellis MD
Fucetola R, Seidman LJ, Kremen WS,

Faraone SV, Goldstein JM, Tsuang MT. Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers, 137
Fujita M, Charney DS, Innis RB. Imaging serotonergic neurotransmission in depression: hippocampal pathophysiology may mirror global brain alterations, 801

Gage FH. Structural plasticity: cause, result, or correlate of depression, 713-ed
Gambhir SS. See MacLaren DC
Gary KA. See Winokur A
Gebre-Medhin P. See Tohen M
George EL. See Miklowitz DJ
George MS. See Osuch EA
George MS, Nahas Z, Molloy M, Speer AM, Oliver NC, Li X-B, Arana GW, Risch SC, Ballenger JC. A controlled trial of daily left prefrontal cortex TMS for treating depression, 962
Gerner R. See Altshuler LL
Geva AB. See Peled A
Gharaibeh WS, Rohlf FJ, Slice DE, DeLisi LE. A geometric morphometric assessment of change in midline brain structural shape following a first episode of schizophrenia, 398
Gilbert A. See Rosenberg DR
Gilmore JH. See Jarskog LF
Glantz LA, Austin MC, Lewis DA. Normal cellular levels of synaptophysin mRNA expression in the prefrontal cortex of subjects with schizophrenia, 389
Glitz DA. See Moore GJ
Goff DC. See Heckers S
Goff DC. See Manoach DS
Gold JM, Bish JA, Iannone VN, Hobart MP, Queern CA, Buchanan RW. Effects of contextual processing on visual conditional associative learning in schizophrenia, 406
Goldsmith HH, Lemery KS. Linking temperamental fearfulness and anxiety symptoms: a behavior–genetic perspective, 1199
Goldstein G, Fava M, Culler M, Fisher A, Rickels K, Lydiard RB, Rosenbaum J. Elevated plasma thymopoietin associated with therapeutic nonresponsiveness in major depression, 65
Goldstein JM. See Fucetola R
Gollub RL. See Manoach DS
Goodman AB, Pardee AB. Meeting report: "Molecular Neurobiological Mechanisms in Schizophrenia: Seeking a Synthesis," April 11–14, 1999, 173
Gorwood P, Batel P, Adès J, Hamon M, Boni C. Serotonin transporter gene polymorphisms, alcoholism, and suicidal behavior, 259
Gould E, Tanapat P, Rydel T, Hastings N. Regulation of hippocampal neurogenesis in adulthood, 715
Grados MA. See Bienvenu OJ
Green M. See Hua LV
Greenberg DL. See Steffens DC
Greenhouse JB. On clinical trials in psychiatry, 433-ed
Greeno CG. See Frank GK
Greer PJ. See Moses EL
Grieder T. See Altshuler LL
Griez E, van Beek N. Reactivity to a 35% CO_2 challenge in healthy first-degree relatives of patients with panic disorder, 1223-corr (response)
Gross C, Santarelli L, Brunner D, Zhuang X, Hen R. Altered fear circuits in 5-HT_{1A} receptor KO mice, 1157
Grossberg S. The imbalanced brain: from normal behavior to schizophrenia, 81
Grupper D. See Maayan R
Grush L. See Cohen LS
Guarneri L. See Sacchetti E
Gur RC. See Kohler CG
Gur RE. See Kohler CG

Hada M, Porjesz B, Begleiter H, Polich J. Auditory P3a assessment of male alcoholics, 276
Hagendoorn M. See Kohler CG
Halaris A. See Piletz JE
Halbreich U. See Piletz JE
Hall J. See De Bellis MD
Halpern E. See Manoach DS
Hamon M. See Gorwood P
Hanna GL. See Rosenberg DR
Hardy P. See Bellivier F
Hare RD. See Kiehl KA
Haroutunian V. See Sokolov BP
Harris JG. See Ross RG
Hasanat K. See Moore GJ
Hastings N. See Gould E
Hätönen T. See Lindblom N
Hauffa BP. See Meyer G
Hauger R. See Parry BL
Hayakawa T. See Shibui K
Hayes JB. See Winokur A
Heckers S, Curran T, Goff D, Rauch SL, Fischman AJ, Alpert NM, Schacter DL. Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia, 651
Heller VL. See Cohen LS
Hen R. See Gross C
Heninger GR. See Moreno FA
Hennen J. See Steingard RJ
Hennen J. See Tohen M
Henry C. See Bellivier F
Herbert J. See Michael A
Herrmann WM. See Kraemer S
Herschman HR. See MacLare DC
Herscovitch P. See Osuch EA
Herscovitch P. See Speer AM
Hill SY, Shen S, Lowers L, Locke J. Factors predicting the onset of adolescent drinking in families at high risk for developing alcoholism, 265
Hirschmann S. See Peled A
Hobart MP. See Gold JM
Hoehn-Saric R. See Bienvenu OJ
Hostetter A, Ritchie JC, Stowe ZN. Amniotic fluid and umbilical cord blood concentrations of antidepressants in three women, 1032
Hua LV, Green M, Warsh JJ, Li PP. Lithium regulation of aldolase A expression in the rat frontal cortex: identification by differential display, 58
Hyman SE. Goals for research on bipolar disorder: the view from NIMH, 436

Iacono WG. See Sponheim SR
Iannone VN. See Gold JM
Innis RB. See Fujita M
Ishibashi K. See Shibui K

Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA. Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia, 641
Jauss M, Pantel J, Werle E, Schröder J. G-CSF plasma levels in clozapine-induced neutropenia, 1113
Javeed S. See Parry BL
Jenaway A. See Michael A
Jentsch JD, Roth RH, Taylor JR. Object retrieval/detour deficits in monkeys

produced by prior subchronic phencyclidine administration: evidence for cognitive impulsivity, 415
Jerabek PA. See Liotti M
Jerabek PA. See Mayberg HS
Jimenez T. See Altshuler LL
Jolkovsky L. See Moore GJ

Kalbag A. See Miklowitz DJ
Kalin NH. See Bakshi VP
Kalro BN. See Moses EL
Kamei Y. See Shibui K
Kaoud MA. See Maayan R
Katic A. See Steingard RJ
Kaufman J. See Dahl RE
Kaufman J, Plotsky PM, Nemeroff CB, Charney DS. Effects of early adverse experiences on brain structure and function: clinical implications, 778
Kaufman MJ. See Christensen JD
Kaye WH. See Frank GK
Keck ME. See Müller MB
Keck PE Jr. See McElroy SL
Keck PE Jr. See Rush AJ
Keck PE Jr. Treatment advances in biplolar disorder—making up for lost time, 430-ed
Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia, 627
Kendler KS. See Young EA
Keshavan MS. See Stanley JA
Keshavan MS, Stanley JA, Pettegrew JW. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings—part II, 369
Ketter TA. See Osuch EA
Kiehl KA, Smith AM, Hare RD, Liddle PF. An event-related potential investigation of response inhibition in schizophrenia and psychopathy, 210
Kim J-J. See Crespo-Facorro B
Kim K. See Shibui K
Kimbrell TA. See Osuch EA
Kimbrell TA. See Speer AM
King S. See Lupien SJ
Kinsella A. See Quinn J
Kirshman KRK. See Lai T-J
Kleinman JE. See Vawter MP
Kmiec JA. See Sweeney JA
Knight DL. See Owens MJ
Koch S. See Moore GJ
Kocsis JH. See Blumberg HP
Kohler CG, Bilker W, Hagendoorn M, Gur RE, Gur RC. Emotion recognition deficit in schizophrenia: association with symptomatology and cognition, 127
Kraemer S, Danker-Hopfe H, Dorn H, Schmidt A, Ehlert I, Herrmann WM. Time-of-day variations of indicators of attention: performance, physiologic parameters, and self-assessment of sleepiness, 1069
Kremen WS. See Faraone SV
Kremen WS. See Fucetola R
Krishnan KRR. See Steffens DC
Kudo Y. See Shibui K
Kupfer DJ. See Frank E
Kupfer DJ. See Sweeney JA
Kupfer DJ. Models of bipolar disease and their clinical implications, 428-ed

Laakso M-L. See Lindblom N
Lacoste J. See Bellivier F
Lai T-J, Payne ME, Byrum CE, Steffens DC, Kirshman KRK. Reduction of orbital frontal cortex volume in geriatric depression, 971
Laipio M-L. See Lindblom N
Landgraf R. See Müller MB
Lane A. See Quinn J
Laplanche J-L. See Bellivier F
Larach VW. See DeLisi LE
Laruelle M. See Kegeles LS
Laruelle M. See Martinez D
Lasko M. See Shin LM
Laughlin GA. See Parry BL
Launay J-M. See Bellivier F
Launay J-M. See Leboyer M
Lavori PW, Dawson R, Rush AJ. Flexible treatment strategies in chronic disease: clinical and research implications, 605
Lawson JS. See David MM
Leboyer M. See Bellivier F
Leboyer M, Launay J-M. Cautionary note: complex (dys)function of the serotonin transporter, 335-corr (response)
Leight K. See Altshuler LL
Lemery KS. See Goldsmith HH
Lenox RH. See Manji HK
Leondires MP. See Moses EL
Lewine RJ. See Walder DJ
Lewis DA. See Glantz LA
Lewis L. A consumer perspective concerning the diagnosis and treatment of bipolar disorder, 442
Li PP. See Emamghoreishi M
Li PP. See Hua LV
Li X-B. See George MS
Liang K-Y. See Bienvenu OJ
Liddle PF. See Kiehl KA
Lieberman JA. See Jarskog LF
Lindblom N, Hätönen T, Laakso M-L, Alila-Johansson A. Laipio M-L, Turpeinen U. Bright light exposure of a large skin area does not affect melatonin or bilirubin levels in humans, 1098
Liotti M. See Pliszka SR
Liotti M, Mayberg HS, Brannan SK, McGinnis S, Jerabek P, Fox PT. Differential limbic–cortical correlates of sadness and anxiety in healthy subjects: implications for affective disorders, 30
Liu X. See Shibui K
Locke J. See Hill SY
Loftus J. See DeLisi LE
Lopresti B. See Moses EL
Loucks TL. See Moses EL
Lowers L. See Hill SY
Lu Y. See Rollema H
Lukas SE. See Christensen JD
Lupien SJ. Stress and schizophrenia: the importance of cognition, 1119-ed
Lupien SJ, King S, Meaney MJ, McEwen BS. Child's stress hormone levels correlate with mother's socioeconomic status and depressive state, 976
Lydiard RB. See Goldstein G

Maayan R, Yagorowski Y, Grupper D, Weiss M, Shtaif B, Kaoud MA, Weizman A. Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients, 693
MacDonald MM. See Winokur A
MacFall JR. See Steffens DC
Macklin ML. See Shin LM
MacLaren DC, Toyokuni T, Cherry SR, Barrio JR, Phelps ME, Herschman HR, Gambhir SS. PET imaging of transgene expression, 337
Maffei C. See Battaglia M
Magnotta V. See Crespo-Facorro B
Mahurin RK. See Mayberg HS

Malberg J. See Duman RS
Mangold D, McCaul ME, Ali M, Wand GS. Plasma adrenocorticotropin responses to opioid blockade with naloxone: generating a dose–response curve in a single session, 310
Manji HK. See Moore GJ
Manji HK, Lenox RH. Signaling: cellular insights into the pathophysiology of bipolar disorder, 518
Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic–depressive illness, 740
Mann JJ. See Kegeles LS
Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E, Saper CB, Rauch SL. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance, 99
Marino C. See Battaglia M
Martinez D. See Blumberg HP
Martinez D, Broft A, Laruelle M. Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies, 844
Mathis CA. See Moses EL
Mayberg HS. See Liotti M
Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S. Jerabek PA. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response, 830
McBride PA. See Blumberg HP
McCarley RW. See Niznikiewicz MA
McCaul ME. See Mangold D
McElroy SL. See Rush AJ
McElroy SL, Keck PE Jr. Pharmacologic agents for the treatment of acute bipolar mania, 539
McEwen BS. See Lupien SJ
McEwen BS. Effects of adverse experiences for brain structure and function, 721
McGahuey CA. See Moreno FA
McGinnis S. See Liotti M
McGinnis S. See Mayberg HS
McQuoid DR. See Steffens DC
Meaney MJ. See Caldji C
Meaney MJ. See Lupien SJ
Meltzer HY. See Miguel-Hidalgo JJ
Mendelson JH. See Christensen JD
Meng F. See Watson SJ
Meyer G, Hauffa BP, Schedlowski M, Pawlak C, Stadler MA, Exton MS. Casino gambling increases heart rate and salivary cortisol in regular gamblers, 948
Michael A, Jenaway A, Paykel ES, Herbert J. Altered salivary dehydroepiandrosterone levels in major depression in adults, 989
Mick E. See Biederman J
Mick E. See Faraone SV
Miguel-Hidalgo JJ, Baucom C, Dilley G, Overholser JC, Meltzer HY, Stockmeier CA, Rajkowska G. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder, 861
Miklowitz DJ, Simoneau TL, George EL, Richards JA, Kalbag A, Sachs-Ericsson N, Suddath R. Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy, 582
Mintz J. See Altshuler LL
Modai I. See Peled A
Moldin SO. Neurobiology of anxiety and fear: challenges for genomic science of the new millennium, 1144
Molloy M. See George MS
Molteni M. See Battaglia M
Monuteaux MC. See Biederman J
Monuteaux MC. See Faraone SV
Moore CM. See Christensen JD
Moore CM. See Steingard RJ
Moore GJ. See Manji HK
Moore GJ. See Rosenberg DR
Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, Faulk MW, Koch S, Glitz DA, Jolkovsky L, Manji HK. Lithium increases *N*-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?, 1
Moore JC. See Steingard RJ
Moore P. See Bardwell WA
Moran M. See Quinn J
Moreno FA, Heninger GR, McGahuey CA, Delgado PL. Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes, 327
Moses EL, Drevets WC, Smith G, Mathis CA, Kalro BN, Butters MA, Leondires MP, Greer PJ, Lopresti B, Loucks TL, Berga SL. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study, 854
Müller MB, Landgraf R, Keck ME. Vasopressin, major depression, and hypothalamic–pituitary–adrenocortical desensitization, 330
Murray C. See Woodward SH

Nahas Z. See George MS
Nakagawa S. See Duman RS
Nemeroff CB. See Kaufman J
Nemeroff CB. See Owens MJ
Neria Y, Bromet EJ. Comorbidity of PTSD and depression: linked or separate incidence, 878-ed
Nestadt G. See Bienvenu OJ
Niznikiewicz MA, Voglmaier MM, Shenton ME, Dickey CC, Seidman LJ, Teh E, Van Rhoads R, McCarley RW. Lateralized P3 deficit in schizotypal personality disorder, 702
Nobile M. See Battaglia M
Nolen WA. See Rush AJ
Nosten-Bertrand M. See Bellivier F

Ogliari A. See Battaglia M
Ohta K. See Shibui K
Okawa M. See Shibui K
O'Leary DS. See Crespo-Facorro B
O'Leary DS. See Sears LL
Olincy A. See Ross RG
Oliver NC. See George MS
Ordway G. See Piletz JE
Orr SP. See Shin LM
Osuch EA, Ketter TA, Kimbrell TA, George MS, Benson BE, Willis MW, Herscovitch P, Post RM. Regional cerebral metabolism associated with anxiety symptoms in affective disorder patients, 1020
Overholser JC. See Miguel-Hidalgo JJ
Owen JA. See David MM
Owens MJ, Nemeroff CB, Knight DL. Paroxetine binding to the rat

norepinephrine transporter in vivo, 954-corr (response) Özkul Y. See Turan MT

Palagini L. See Tan X
Pantel J. See Jauss M
Pardee AB. See Goodman AG
Parikh SV. See Emamghoreishi M
Parry BL, Javeed S, Laughlin GA, Hauger R, Clopton P. Cortisol circadian rhythms during the menstrual cycle and with sleep deprivation in premenstrual dysphoric disorder and normal control subjects, 920
Pascualy M, Petrie EC, Brodkin K, Peskind ER, Wilkinson CW, Raskind MA. Hypothalamic pituitary adrenocortical and sympathetic nervous system responses to the cold pressor test in Alzheimer's disease, 247
Pawlak C. See Meyer G
Paykel ES. See Michael A
Payne ME. See Lai T-J
Payne ME. See Steffens DC
Peled A, Ritsner M, Hirschmann S, Geva AB, Modai I. Touch feel illusion in schizophrenic patients, 1105
Pepple JR. See Faraone SV
Perel J. See Dahl RE
Peskind ER. See Pascualy M
Peterson EL. See Breslau N
Petrie EC. See Pascualy M
Pettegrew JW. See Keshavan MS
Pettegrew JW. See Stanley JA
Phelps ME. See MacLaren DC
Piletz JE, Halbreich U. Imidazoline and α_{2A}-adrenoceptor binding sites in postmenopausal women before and after estrogen replacement therapy, 932
Piletz JE, Zhu H, Ordway G, Stockmeier C, Dilley G, Reis D, Halaris A. Imidazoline receptor proteins are decreased in the hippocampus of individuals with major depression, 910
Pitman RK. See Shin LM
Pliszka SR, Liotti M, Woldorff MG. Inhibitory control in children with attention-deficit/hyperactivity disorder: event-related potentials identify the processing component and timing of an impaired right-frontal response-inhibition mechanism, 238
Plotsky PM. See Kaufman J
Polich J. See Hada M
Porjesz B. See Hada M
Post RM. See Osuch EA
Post RM. See Rush AJ
Post RM. See Speer AM
Prescott CA. See Young EA

Queern CA. See Gold JM
Quinn J, Moran M, Lane A, Kinsella A, Waddington JL. Long-term adaptive life functioning in relation to initiation of treatment with antipsychotics over the lifetime trajectory of schizophrenia, 163

Radant A. See Ross RG
Raimonde AJ. See Delahanty DL
Rajkowska G. See Miguel-Hidalgo JJ
Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells, 766
Raskind MA. See Pascualy M
Rauch SL. See Heckers S
Rauch SL. See Manoach DS
Rauch SL. See Shin LM
Razi K. See DeLisi LE
Reis D. See Piletz JE
Reite M. See Teale P
Relja M. See DeLisi LE
Renshaw PF. See Christensen JD
Renshaw PF. See Steingard RJ
Renshaw PF. See Stoll AL
Repella J. See Speer AM
Richards JA. See Miklowitz DJ
Rickels K. See Goldstein G
Ricketts S. See Blumberg HP
Riddle MA. See Bienvenu OJ
Risch SC. See George MS
Ritchie JC. See Hostetter A
Ritsner M. See Peled A
Rodenhiser-Hill J. See Kegeles LS
Rohlf FJ. See Gharaibeh WS
Rojas DC. See Teale P
Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. 5-HT_{1A} receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex, 229
Rose SL. See Christensen JD
Rosenbaum J. See Goldstein G
Rosenberg DR, Benazon NR, Gilbert A, Sullivan A, Moore GJ. Thalamic volume in pediatric obsessive–compulsive disorder patients before and after cognitive behavioral therapy, 294
Rosenberg DR, Hanna GL. Genetic and imaging strategies in obsessive–compulsive disorder: potential implications for treatment development, 1210
Ross RG, Olincy A, Harris JG, Sullivan B, Radant A. Smooth pursuit eye movements in schizophrenia and attentional dysfunction: adults with schizophrenia, ADHD, and a normal comparison group, 197
Roth RH. See Jentsch JD
Rouillon F. See Bellivier F
Rubin RT. Paroxetine binding to the rat norepinephrine transporter in vivo, 954-corr
Rush AJ. See Lavori PW
Rush AJ, Post RM, Nolen WA, Keck PE Jr, Suppes T, Altshuler L, McElroy SL. Methodological issues in developing new acute treatments for patients with bipolar illness, 615
Ryan ND. See Dahl RE
Ryan ND. See De Bellis MD
Rydel T. See Gould E

Sacchetti E, Guarneri L, Bravi D. H_2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients, 167
Sachs-Ericsson N. See Miklowitz DJ
Sachs GS. See Thase ME
Sachs GS, Thase ME. Bipolar disorder therapeutics: maintenance treatment, 573
Sackeim HA. See Chanpattana W
Sackeim HA. Repetitive transcranial magnetic stimulation: what are the next steps?, 959-ed
Samuels JF. See Bienvenu OJ
Sanberg PR. See Shytle RD
Santarelli L. See Gross C
Saper CB. See Manoach DS
Sapolsky RM. See Brooke SM
Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death, 755
Sateia MJ. See Winokur A
Schacter DL. See Heckers S
Schedlowski M. See Meyer G
Schlichter L. See Emamghoreishi M
Schmidt A. See Kraemer S
Schmidt AW. See Rollema H
Schröder J. See Jauss M

Schultz LR. See Breslau N
Searl MM. See Manoach DS
Sears LL, Andreasen NC, O'Leary DS. Cerebellar functional abnormalities in schizophrenia are suggested by classical eyeblink conditioning, 204
Seidman LJ. See Faraone SV
Seidman LJ. See Fucetola R
Seidman LJ. See Niznikiewicz MA
Selinger ES. See Jarskog LF
Sellaro S. See Angst J
Seraji-Bozorgzad N. See Moore GJ
Sheeder J. See Teale P
Sheline YI. 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity, 791
Shen S. See Hill SY
Shenton ME. See Niznikiewicz MA
Shibui K, Uchiyama M, Okawa M, Kudo Y, Kim K, Liu X, Kamei Y, Hayakawa T, Akamatsu T, Ohta K, Ishibashi K. Diurnal fluctuation of sleep propensity and hormonal secretion across the menstrual cycle, 1062
Shields G. See DeLisi LE
Shin LM, Dougherty DD, Orr SP, Pitman RK, Lasko M, Macklin ML, Alpert NM, Fischman AJ, Rauch SL. Activation of anterior paralimbic structures during guilt-related script-driven imagery, 43
Shtaif B. See Maayan R
Shytle RD, Silver AA, Sanberg PR. Comorbid bipolar disorder in Tourette's syndrome responds to the nicotinic receptor antagonist mecamylamine (inversine), 1028
Siever LJ. Antidepressant selection in the postgenomic era, 875-ed
Silbersweig DA. See Blumberg HP
Silva JA. See Mayberg HS
Silver AA. See Shytle RD
Simoneau TL. See Miklowitz DJ
Slice DE. See Gharaibeh WS
Smith AB. See DeLisi LE
Smith AM. See Kiehl KA
Smith G. See Moses EL
Sofuoğlu S. See Turan MT
Sokolov BP, Tcherepanov AA, Haroutunian V, Davis KL. Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients, 184
Southmayd SE. See David MM
Speer AM. See George MS
Speer AM, Kimbrell TA, Wassermann EM, Repella J, Willis MW, Herscovitch P, Post RM. Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients, 1133
Spencer T. See Biederman J
Spencer T. See Faraone SV
Sponheim SR, Clementz BA, Iacono WG, Beiser M. Clinical and biological concomitants of resting state EEG power abnormalities in schizophrenia, 1088
Spoonster E. See Delahanty DL
Sprouse JS. See Rollema H
Stadler MA. See Meyer G
Stahl SM. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline, 894
Stanley JA. See Keshavan MS
Stanley JA, Pettegrew JW, Keshavan MS. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings—part I, 357
Steffens DC. See Lai T-J
Steffens DC, Byrum CE, McQuoid DR, Greenberg DL, Payne ME, Blitchington TF, MacFall JR, Krishnan KRR. Hippocampal volume in geriatric depression, 301
Stein MB. Reactivity to a 35% CO_2 challenge in healthy first-degree relatives of patients with panic disorder, 1223-corr
Steingard RJ, Yurgelun-Todd DA, Hennen J, Moore JC, Moore CM, Vakili K, Young AD, Katic A, Beardslee WR, Renshaw PF. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy, 1053
Stern E. See Blumberg HP
Stewart J. See DeLisi LE
Stockmeier C. See Piletz JE
Stockmeier CA. See Miguel-Hidalgo JJ
Stoll AL. See Tohen M
Stoll AL, Renshaw PF, Yurgelun-Todd DA, Cohen BM. Neuroimaging in bipolar disorder: what have we learned?, 505
Stone WS. See Tsuang MT
Stowe ZN. See Hostetter A
Strakowski SM. See Tohen M
Strakowski SM, DelBello MP, Fleck DE, Arndt S. The impact of substance abuse on the course of bipolar disorder, 477
Suddath R. See Miklowitz DJ
Sullivan A. See Rosenberg DR
Sullivan B. See Ross RG
Suppes T. See Rush AJ
Suppes T. See Tohen M
Swartz HA. See Frank E
Sweeney JA, Kmiec JA, Kupfer DJ. Neuropsychologic impairments in bipolar and unipolar mood disorders on the CANTAB neurocognitive battery, 674
Szöke A. See Bellivier F

Tan X, Campbell IG, Palagini L, Feinberg I. High internight reliability of computer-measured NREM delta, sigma, and beta: biological implications, 1010
Tanapat P. See Gould E
Taylor JR. See Jentsch JD
Tcherepanov AA. See Sokolov BP
Teale P, Reite M, Rojas DC, Sheeder J, Arciniegas D. Fine structure of the auditory M100 in schizophrenia and schizoaffective disorder, 1109
Teh E. See Niznikiewicz MA
Tekell JL. See Mayberg HS
Thase ME. See Sachs GS
Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies, 558
The HT. See Flentge F
Thomas KM. See De Bellis MD
Thompson RC. See Watson SJ
Tohen M, Strakowski SM, Zarate C Jr, Hennen J, Stoll AL, Suppes T, Faedda GL, Cohen BM, Gebre-Medhin P, Baldessarini RJ. The McLean–Harvard First-Episode Project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis, 467
Tomaskovic-Crook E. See Crook JM
Toomey R. See Faraone SV
Toyokuni T. See MacLaren DC
Tsuang MT. See Faraone SV
Tsuang MT. See Fucetola R
Tsuang MT, Stone WS, Faraone SV. Towards the prevention of schizophrenia, 349
Turan MT, Eşel E, Dündar M. Candemir Z, Baştürk M, Sofuoğlu S,

Özkul Y. Female-to-male transsexual with 47,XXX karyotype, 1116
Turpeinen U. See Lindblom N

Uchiyama M. See Shibui K
Uhde TW. Genetics and brain function: implications for the treatment of anxiety, 1142-ed

Vakili K. See Steingard RJ
van Beek N. See Griez E
van den Berg MD. See Flentge F
Van Heertum RL. See Kegeles LS
Van Rhoads R. See Niznikiewicz MA
Vawter MP, Freed WJ, Kleinman JE. Neuropathology of bipolar disorder, 486
Vita A. See DeLisi LE
Voglmaier MM. See Niznikiewicz MA

Waddington JL. See Quinn J
Walder DJ, Walker EF, Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia, 1121
Walker EF. See Walder DJ
Wand GS. See Mangold D
Wang JF. See Chen B
Warsh JJ. See Emamghoreishi M
Warsh JJ. See Hua LV
Wassermann EM. See Speer AM
Watson SJ, Meng F, Thompson RC, Akil H. The "chip" as a specific genetic tool, 1147
Weiss M. See Maayan R
Weizman A. See Maayan R
Wellman N. See DeLisi LE
Werle E. See Jauss M
White T. See Blumberg HP
Wilds IB. See Moore GJ
Wilens T. See Faraone SV
Wilens TE. See Biederman J
Wilkins J. See Altshuler LL
Wilkinson CW. See Pascualy M
Williamson DE. See Dahl RE
Williamson DE. See De Bellis MD
Willis MW. See Osuch EA
Willis MW. See Speer AM
Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM, Gary KA. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study, 75
Woldorff MG. See Pliszka SR
Woodward SH, Arsenault NJ, Murray C, Bliwise DL. Laboratory sleep correlates of nightmare complaint in PTSD inpatients, 1081
Wooltorton E. See David MM
Wozniak J. See Biederman J

Yagorowski Y. See Maayan R
Young AD. See Steingard RJ
Young EA, Aggen SH, Prescott CA, Kendler KS. Similarity in saliva cortisol measures in monozygotic twins and the influence of past major depression, 70
Young LT. See Chen B
Yurgelun-Todd DA. See Steingard R
Yurgelun-Todd DA. See Stoll AL

Zarate C Jr. See Tohen M
Zea-Ponce Y. See Kegeles LS
Zhu H. See Piletz JE
Zhuang X. See Gross C
Zorn SH. See Rollema H

Subject Index to Volume 48

N-Acetyl-aspartate levels
  lithium affecting, 740
ACTH. *See also* Corticotropin-releasing hormone
  plasma levels after naloxone, 310
  response to cold pressor test in Alzheimer's disease, 247
Adaptive life functioning
  in schizophrenia, 163
Addiction
  gambling affecting heart rate and salivary cortisol, 948
  serotonin transporter gene polymorphisms in, 259
Adenylyl cyclase activity
  and signaling in bipolar disorder, 518
    calcium homeostasis affecting, 665
Adolescence
  depression in, orbitofrontal cytosolic choline levels in, 1053
  factors in onset of alcohol use, 265
Adrenal steroids
  and hippocampal neurogenesis, 801
  and hippocampal neuron loss in depression, 755
  and neurogenesis in adults, 715
  and neurotoxicity in HIV infection, 881
  and prefrontal cortex cell loss in depression, 766
  and structural plasticity of hippocampus, 721
α_{2A}-Adrenoceptors
  binding sites affected by estrogen, 932
Affective disorders
  neural correlates of sadness and anxiety, 30
  and suicidal behavior related to serotonin transporter gene polymorphism, 259, 319
  and thyroid function in sleep deprivation, 323
Age
  and brain morphology in schizophrenia, 398
  and glial fibrillary acidic protein immunoreactivity in depression, 861
  and neuropsychologic function in schizophrenia, 137
Aged subjects
  hippocampal volume in geriatric depression, 301
  increased natural killer T cells in depression, 1024
  reduced orbitofrontal cortex volume in depression, 971
  synaptic proteins in schizophrenia, 184
AIDS-related dementia complex
  and neurotoxicity affected by steroid hormones, 881
Alcoholism
  association with bipolar and conduct disorders, 1037
  auditory P3a in male alcoholics, 276
  and course of bipolar disorder, 477
  factors in onset of adolescent alcohol use, 265
  and pediatric mania, 458
  serotonin transporter gene polymorphisms in, 259
Aldolase A
  brain levels affected by lithium, 58
Alzheimer disease
  cold pressor test in, 247
Amniotic fluid
  antidepressant concentrations in, 1032
cAMP
  response element–binding protein
    affecting cell survival, 732
    and expression of bcl-2 protein, 740
  signaling in bipolar disorder, 518
    calcium homeostasis affecting, 665
Amphetamine
  and striatal dopamine release affected by ketamine, 627
Amygdala
  MRI of men with bipolar disorder or schizophrenia, 147
  neuroimaging in depression, 813
  in pediatric anxiety, 51
  responses in schizophrenia, 81
Animal studies
  corticotropin-releasing hormone in stress, 1175
  early stress affecting brain structure and function, 778
  fear circuits in 5-HT_A receptor knockout mice, 1157
  lithium regulation of aldolase A expression, 58
  object retrieval deficits from phencyclidine in monkeys, 415
  paroxetine binding to norepinephrine transporter in rats, 954-corr
  PET imaging of transgene expression, 337
  stress reactivity affected by maternal care, 1164
  valproate affecting endoplasmic reticulum stress proteins, 658
  ziprasidone affecting dopamine release in prefrontal cortex, 229
Anorexia nervosa
  CSF oxytocin and vasopressin levels in recovered subjects, 315
Antidepressants
  and adenyl cyclase activity, 518
  affecting serotonin receptors, 801
  augmentation by pindolol, 844
  in bipolar disorder, 558
  comparison of citalopram and sertraline, 894
  concentrations in amniotic fluid, 1032
  as maintenance therapy in bipolar disorder, 573
  selection in postgenomic era, 875-ed
Antiepileptic drugs
  in bipolar mania, 539

Abbreviations:
ed, editorial
corr, correspondence

© 2000 Society of Biological Psychiatry

0006-3223/00/$20.00
PII S0006-3223(00)01104-5

Antipsychotic drugs
and adaptive life functioning in schizophrenia, 163
in bipolar depression, 558
in bipolar mania, 539
as maintenance therapy in bipolar disorder, 573
and molecular mechanisms in schizophrenia, 173
ziprasidone affecting dopamine release in prefrontal cortex, 229
Anxiety
and altered fear circuits in knockout mice, 1158
genetics and brain function, implications for treatment of, 1142-ed
in childhood
amygdala in, 51
and pediatric mania, 458
in mood disorders, cerebral metabolism in, 1020
neural correlates of, 30
neurobiology of, 1145
and nightmares in posttraumatic stress disorder, 1081
and temperamental fearfulness, 1199
Apnea in sleep
and sleep architecture in depression, 1001
Apoptosis
and bcl-2 protein expression in schizophrenia, 641
in mood disorders, 732
mood stabilizers affecting, 740
Arousal systems
and gambling affecting heart rate and salivary cortisol, 948
in schizophrenia, 81
Associative learning in schizophrenia
and cerebellar function, 204
conditional, 406
Astroglia
age affecting glial fibrillary acidic protein immunoreactivity in depression, 861
Attention
time-of-day variations in, 1069
Attention-deficit/hyperactivity disorder
in adults, 9
familial association with conduct disorder, 21
and pediatric mania, 458
response inhibition in, 238
smooth pursuit eye movements in, 197
Auditory event-related potentials
lateralized P3 deficit in schizotypal personality disorder, 702
and onset of adolescent alcohol use, 265
P3a in male alcoholics, 276
Auditory-evoked fields
anomalous lateralization of M100 in psychosis, 1109

B lymphoblasts
calcium homeostasis affecting signaling in bipolar disorder, 665
Basal ganglia
activation in schizophrenia, 99
cocaine affecting, 685
Bcl-2 protein
expression in schizophrenia, 641
lithium affecting, 1
mood stabilizers affecting, 740
Behavioral therapy
and thalamic volume in pediatric obsessive–compulsive disorder, 294
Bilirubin
serum levels affected by skin light exposure, 1098
Bipolar disorder
antidepressants in, 558
antimanic agents in, 539
association with conduct disorder and substance use, 1037
calcium homeostasis and cAMP signaling in, 665
cingulate and caudate activity in mania, 1045
course affected by substance abuse, 477
development of acute phase treatments, 615
and evaluation of clinical trials in psychiatry, 433-ed
family therapy in, 582
flexible treatment strategies, 605
interpersonal and social rhythm therapy, 593
lithium affecting *N*-acetyl-aspartate levels in brain, 1
lithium regulation of aldolase A expression, 58
maintenance treatment, 573
models of, 426-ed
MRI of temporal lobe structures in men, 147
natural history of, 445
neuroimaging in, 505
neuropathology of, 486
neuropsychologic findings in, 674
neurotrophic effects of mood stabilizers, 740
and pediatric mania, 458
perspectives of National Depressive and Manic-Depressive Association, 442
relation to schizophrenia, 531
research goals of NIMH, 436
and response to mecamylamine in Tourette's syndrome, 1028
signal transduction in, 518
subtypes defined, 427-ed
treatment advances, 430-ed
Body dysmorphic disorder
family studies of, 287
Brain
N-acetyl-aspartate levels affected by lithium, 1
activated regions in schizophrenia, 99
aldolase A mRNA levels affected by lithium, 58
amygdala volumes in pediatric anxiety, 51
arousal systems in schizophrenia, 81
cerebellar function in schizophrenia, 204
frontal abnormalities in schizophrenia, 110
frontal lobe cytosolic choline levels in adolescent depression, 1053
functional connectivity alterations in schizophrenia, 1105
genetics and, 1142-ed
hippocampal volume in geriatric depression, 301
lateralization
auditory M100 in psychosis, 1109

auditory P3 deficit in schizotypal personality disorder, 702
magnetic resonance spectroscopy in schizophrenia, 357, 369
metabolism in anxiety with mood disorders, 1020
morphology assessment in schizophrenia, 1088
morphometrics in first-episode schizophrenia, 398
neural correlates of sadness and anxiety, 30
neuroanatomic changes in depression, 791
neuropathology in bipolar disorder, 486
regional blood flow
affected by high and low frequencies in transcranial magnetic stimulation, 1133
cingulate and caudate activity in mania, 1045
in guilt-related imagery, 43
structural plasticity
and cell survival in mood disorders, 732
in depression, 713-ed
in hippocampal remodeling, 721
structure and function after early stress, 778
synaptic proteins in schizophrenia, 184
thalamic volume in pediatric obsessive–compulsive disorder, 294
valproate affecting endoplasmic reticulum stress proteins, 658
Brain-derived neurotrophic factor
affecting cell survival in mood disorders, 732
Bulimia nervosa
CSF oxytocin and vasopressin levels in recovered subjects, 315
Bupropion
in bipolar depression, 558
Buspirone
in bipolar depression, 558

Calcium
and glutamatergic neurotoxicity, 755
homeostasis affecting cAMP signaling in bipolar disorder, 665
Calreticulin
expression affected by valproate, 658
Cambridge Neuropsychological Test Automated Battery
in mood disorders, 674
Cannabis abuse
and course of bipolar disorder, 477
Carbamazepine
and adenyl cyclase activity, 518
and aldolase A expression, 58
as antimanic agent, 539
in bipolar depression, 558
Carbon dioxide challenge test
in relatives of panic disorder patients, 1223-corr
Caudate nucleus
activity in bipolar mania, 1045
Cell adhesion molecules
role in bipolar disorder, 486
Cerebellum
function in schizophrenia, 204
neuropathology in bipolar disorder, 486
Cerebrospinal fluid
oxytocin and vasopressin levels after recovery from eating disorders, 315
Child abuse
affecting brain structure and function, 778
Children
amygdala volumes in anxiety, 51
brain imaging in obsessive–compulsive disorder, 1210
cortisol levels related to mother's depression, 976
familial attention-deficit disorder and conduct disorder comorbidity, 21
growth hormone levels in depression, 981
pediatric mania, 458
temperament related to anxiety, 1199
thalamic volume in obsessive–compulsive disorder, 294
Chlorpromazine
as antimanic agent, 539
Choline
orbitofrontal cytosolic levels in adolescent depression, 1053
Cholinergic system
in hippocampus in schizophrenia, 381
Chromosome studies
abnormalities in transsexualism, 1116
Cingulate gyrus, anterior
activity in bipolar mania, 1045
in guilt-related imagery, 43
metabolic effects of fluoxetine in depression, 830
neuroimaging in depression, 813
Circadian rhythms
cortisol secretion in, 920
interpersonal and social rhythm therapy in bipolar disorder, 593
salivary cortisol levels in twins, 70
salivary dehydroepiandrosterone levels in major depression, 989
sleep and hormonal fluctuations in menstrual cycle, 1062
time-of-day variations in attention, 1069
Citalopram
compared to sertraline, 894
Clinical trials
antimanic agents, 539
in bipolar depression treatment, 558
design for flexible treatment strategies, 605
evaluation of, 433-ed
maintenance therapy in bipolar disorder, 573
transcranial magnetic stimulation in depression, 962
Clomipramine
affecting serotonin receptors, 801
in bipolar depression, 558
Clorgyline
in bipolar depression, 558
Clozapine
as antimanic agent, 539
as maintenance therapy in bipolar disorder, 573
neutropenia from, granulocyte colony–stimulating factor levels in, 1113

Cocaine
basal ganglia changes from, 685
Cognition
deficits in mood disorders, 674
in schizophrenia
and emotion recognition, 127
and episodic object recognition, 651
and reactivity to stress, 1119
and symptom severity related to cortisol release, 1121
Cognitive behavioral therapy
and thalamic volume in pediatric obsessive–compulsive disorder, 294
Cold pressor test
in Alzheimer's disease, 247
Comorbidity
anxiety in affective disorders, 1020
depression and physical illnesses, 791
posttraumatic stress disorder and depression, 878-ed, 902
response to mecamylamine in bipolar disorder with Tourette's syndrome, 1028
Computer analysis
of sleep EEG, reliability of, 1010
Conditional associative learning
in schizophrenia, 406
Conduct disorder
association with bipolar disorder and substance use, 1037
familial association with attention-deficit disorder, 21
and pediatric mania, 458
Connectivity, functional
and touch feel illusion in schizophrenia, 1105
Corpus callosum
morphology in schizophrenia, 398
Cortical regions
disinhibition in male alcoholics, 276
neuropathology in bipolar disorder, 486
valproate affecting endoplasmic reticulum stress proteins, 658
Corticosteroids. *See* Adrenal steroids
Corticotropin-releasing hormone
and animal models of anxiety, 1175
brain levels affected by early stress, 778
and stress reactivity affected by maternal care, 1164
Cortisol
circadian rhythms in, 920
diurnal fluctuation in menstrual cycle, 1062
elevated levels related to symptom severity in schizophrenia, 1121
initial urine samples predicting posttraumatic stress disorder, 940
response to cold pressor test in Alzheimer's disease, 247
salivary levels
in children, related to mother's depression, 976
depression affecting, in twins, 70
gambling affecting, 948
Current Source Density
and auditory P3a in male alcoholics, 276
Dehydroepiandrosterone
and response to electroconvulsive therapy, 693
salivary levels in major depression, 989
Dendrites
stress-induced remodeling, 721
Dentate gyrus
adult neurogenesis in, 715, 721
Dependence
serotonin transporter gene polymorphisms in, 259
Depression. *See also* Bipolar disorder
in aged subjects
hippocampal volume in, 301
increased natural killer T cells in, 1024
reduced orbitofrontal cortex volume in, 971
anxiety with, 30
cerebral metabolism in, 1020
and CSF oxytocin and vasopressin levels in eating disorders, 315
electroconvulsive therapy
in bipolar disorder, 558
response affected by DHEAS levels, 693
and fear circuits in 5-HT_{1A} receptor knockout mice, 1157
and growth hormone levels in children, 981
hippocampal atrophy in, 721
and imidazoline binding sites affected by estrogen, 932
maternal, and cortisol levels in children, 976
neuroimaging studies, 813
neuronal activity and cell survival in, 732
and orbitofrontal cytosolic choline levels in adolescence, 1053
prefrontal cortex cell loss in, 766
in pregnancy, and fluoxetine affecting birth outcomes, 996
and responses to early stress, 778
serotonergic system imaging in, 801
sleep architecture and obstructive sleep apnea in, 1001
structural plasticity in, 713-ed
transcranial magnetic stimulation in, 959-ed, 962
high and low frequencies affecting brain activity, 1133
Depressive disorder, major
age affecting glial fibrillary acidic protein immunoreactivity in, 861
in aged subjects
increased natural killer T cells in, 1024
and reduced orbitofrontal cortex volume, 971
comorbidity
with physical illness, 791
with posttraumatic stress disorder, 878-ed, 902
hippocampal imidazoline receptor proteins in, 910
magnetic resonance imaging of brain changes, 791
mirtazapine affecting sleep in, 75
and neuron death in hippocampus, 755
neuropsychologic findings in, 674
plasma thymopoietin levels in, 65
regional metabolic effects of fluoxetine in, 830
relapse in tryptophan depletion, 327
response to ECT affected by DHEAS levels, 693
and salivary cortisol in twins, 70
salivary dehydroepiandrosterone in, 989

and thyroid function in sleep deprivation, 323
vasopressin levels in, 330
Deprivation
and neurogenesis in adults, 715
Desipramine
affecting serotonin receptors, 801
in bipolar depression, 558
Deterioration
and executive functions in schizophrenia, 137
Developmental psychopathology
attention-deficit/hyperactivity disorder in adults, 9
Diagnostic validity
attention-deficit/hyperactivity disorder in adults, 9
Divalproex
in bipolar depression, 558
Dopamine
amphetamine-induced release affected by ketamine, 627
brain levels in bipolar disorder, 486
D2 receptor reporter gene expression, 337
phencyclidine affecting, and impulsivity in monkeys, 415
release in prefrontal cortex affected by ziprasidone, 229
Dose–response curve
and ACTH levels after naloxone, 310
Dreams
and nightmares in posttraumatic stress disorder, 1081
Drug abuse
association with bipolar and conduct disorders, 1037
basal ganglia changes from cocaine, 685
course of bipolar disorder in cannabis abuse, 477
and impulsivity affected by phencyclidine in monkeys, 415
and pediatric mania, 458

Eating disorders
CSF oxytocin and vasopressin levels in recovered subjects, 315
family studies of, 287
Electroconvulsive therapy
in bipolar depression, 558
efficacy affected by stimulus intensity, 222
responses affected by plasma DHEAS levels, 693
Electroencephalogaphy
power abnormalities in schizophrenia, 1088
in sleep, reliability of computer analysis in, 1010
Emotion
recognition deficit in schizophrenia, 127
Endoplasmic reticulum
stress proteins affected by valproate, 658
Environment
interactions with genetic factors, 1175
and neurogenesis in adults, 715
and responses to antidepressants, 875-ed
and stress reactivity affected by maternal care, 1164
Epigenetics
and parent-of-origin effect in schizophrenia, 706
Epinephrine
response to cold pressor test in Alzheimer's disease, 247
Erratum
Thase article (1997;41:964–973), 171
Esthesioneuroblastoma, olfactory
and vasopressin levels in depression, 330
Estradiol
affecting serotonin receptor binding, 854
Estrogen
affecting imidazoline and α_{2A}-adrenoceptor binding sites, 932
and neurotoxicity in HIV infection, 881
Event-related potentials
auditory
lateralized P3 deficit in schizotypal personality disorder, 702
and onset of adolescent alcohol use, 265
P3a in male alcoholics, 276
visual
and onset of adolescent alcohol use, 265
and response inhibition in attention-deficit disorder, 238
and response inhibition in schizophrenia or psychopathy, 210
Excitotoxins
and hippocampal neuron loss, 755
Executive functions
age affecting, in schizophrenia, 137
Expressed emotion
in family therapy of bipolar disorder, 582
Eye movements
assessment in schizophrenia, 1088
smooth pursuit in attentional dysfunction, 197
Eyeblink conditioning
and cerebellar function in schizophrenia, 204

Families
attention-deficit disorder and conduct disorder in girls, 21
carbon dioxide challenge test in relatives of panic disorder patients, 1223-corr
cortisol levels in children related to mother's depression, 976
factors in adolescent alcohol use, 265
maternal care in infancy affecting stress reactivity, 1164
neuropsychologic deficits in relatives of schizophrenic patients, 120
obsessive–compulsive disorder and other spectrum conditions, 287
parent-of-origin effect in schizophrenia, 706
risk analysis of association between three disorders, 1037
susceptibility to schizophrenia and bipolar disorder, 531
Family therapy
in bipolar disorder, 582
Fear
altered circuits in knockout mice, 1157
neurobiology of, 1144
and temperament linked to anxiety, 1199
First episodes
and brain morphometrics in schizophrenia, 398
and 6-month outcome measures, 467
Fluoxetine
in bipolar depression, 558
in pregnancy, affecting birth outcomes, 996
regional metabolic effects in depression, 830

Frontal lobe
aldolase A expression affected by lithium, 58
cytosolic choline levels in adolescent depression, 1053
dysfunction in male alcoholics, 276
structural abnormalities in schizophrenia, 110

G proteins
activity in bipolar disorder, 486
and calcium homeostasis, 665
and signal transduction, 518
$GABA_A$ receptor
and response to ECT affected by plasma DHEAS levels, 693
and stress reactivity affected by maternal care, 1164
Gabapentin
as antimanic agent, 539
in bipolar depression, 558
Gambling
heart rate and salivary cortisol in, 948
Gender
attention-deficit disorder and conduct disorder in girls, 21
auditory P3a in male alcoholics, 276
and brain morphology in schizophrenia, 398
and emotion recognition in schizophrenia, 127
MRI in bipolar disorder or schizophrenia in men, 147
Gender identity disorder
and sex chromosome abnormality in transsexualism, 1116
Gene expression
aldolase A mRNA levels affected by lithium, 58
and mRNAs encoding synaptic proteins in schizophrenia, 184
Genetic factors
and brain function, 1142-ed
in childhood anxiety, 1199
in familial attention-deficit disorder and conduct disorder, 21
interactions with environmental factors, 1175
linkage of bipolar disorder and schizophrenia, 531
molecular mechanisms in schizophrenia, 173
neuropsychologic deficits in relatives of schizophrenic patients, 120
no parent-of-origin effect in schizophrenia, 706
in obsessive–compulsive disorder, 1210
PET imaging of transgene expression, 337
in responses to antidepressants, 875-ed
serotonin transporter gene polymorphisms in disorders, 259, 319
sex chromosome abnormality in transsexualism, 1116
Genomics
data analysis issues in microarray technology, 1147
and neurobiology of anxiety and fear, 1144
Glial cells
decreased numbers in bipolar disorder, 486
loss in prefrontal cortex in depression, 766
Glial fibrillary acidic protein
immunoreactivity in depression affected by age, 861
Glucocorticoids. *See* Adrenal steroids
Glucose metabolism, cerebral
in anxiety with affective disorders, 1020
regional effects of fluoxetine in depression, 830
Glutamate
and dopamine responses to amphetamine, 627
interactions with serotonin in obsessive–compulsive disorder, 1210
and neurotoxicity in hippocampus, 755
Glycogen synthase kinase 3β
and therapeutic effects of mood stabilizers, 740
Go/No Go task
and response inhibition in schizophrenia or psychopathy, 210
gp120
neurotoxicity in HIV infection affected by glucocorticoids, 881
Granulocyte colony–stimulating factor
plasma levels in clozapine-induced neutropenia, 1113
Gray matter volume
lithium affecting, 740
Growth hormone
serum levels in depressed children, 981
GRP78 and GRP94
expression affected by valproate, 658
Guilt-related imagery
PET studies of, 43

Haloperidol
as antimanic agent, 539
Heart rate
gambling affecting, 948
Herpes simplex virus
thymidine kinase reporter gene expression, 337
Hippocampus
abnormalities affecting cognition in schizophrenia, 1121
imidazoline receptor proteins in depression, 910
metabolic effects of fluoxetine in depression, 830
MRI of men with bipolar disorder or schizophrenia, 147
muscarinic receptors in schizophrenia, 381
neurogenesis in adults, 715
neuron death in depression, 755
structural plasticity, 721
in mood disorders, 732
valproate affecting endoplasmic reticulum stress proteins, 658
volume loss in depression, 791
in aged subjects, 301
Histamine
H_2 antagonist preventing weight gain in schizophrenia, 166
HIV infection
and neurotoxicity affected by steroid hormones, 881
Hypochondriasis
family studies of, 287
Hypothalamic–pituitary–adrenal axis
cold pressor test in Alzheimer's disease, 247
and depression affecting salivary cortisol levels, 70
desensitization of, and vasopressin levels in depression, 330
function in depression, 791, 801
stress affecting, 721

[^{123}I]IBZM infusions
and ketamine modulation of dopamine release, 627
Imidazoline
binding sites affected by estrogen, 932
receptor proteins in hippocampus in depression, 910
Imipramine
in bipolar depression, 558
Immunology
natural killer T cells in aged depressed patients, 1024
Imprinting
and parent-of-origin effect in schizophrenia, 706
Impulsivity
family studies of, 287
in monkeys, phencyclidine affecting, 415
serotonin transporter gene polymorphisms in, 259
Inhibitory control
phencyclidine affecting, in monkeys, 415
Insomnia
in depression, mirtazapine affecting, 75
Insular lobe
in guilt-related imagery, 43
Interpersonal psychotherapy
in bipolar disorder, 593
Isocarboxazid
in bipolar depression, 558

Ketamine
and amphetamine-induced dopamine release, 627
Knockout mice
deletion of corticotropin-releasing hormone receptors, 1175
fear circuits in 5-HT$_{1A}$ receptor knockout, 1157

Lamotrigine
as antimanic agent, 539
in bipolar depression, 558
Lateralization in brain
auditory M100 in psychosis, 1109
auditory P3 deficit in schizotypal personality disorder, 702
Learning, associative
in schizophrenia, 406
cerebellar function in, 204
Life events
and interpersonal and social rhythm therapy in bipolar disorder, 593
Light
phototherapy in bipolar depression, 558
skin exposure affecting melatonin and bilirubin levels, 1098
Limbic system
brain circuit
changes in depression, 791
neuroimaging in depression, 813
function in depression, 801
MRI of men with bipolar disorder or schizophrenia, 147
neuropathology in bipolar disorder, 486
paralimbic structures in guilt-related imagery, 43
in sadness and anxiety, 30
Lithium
affecting *N*-acetyl-aspartate levels in brain, 1
and aldolase A expression in brain, 58
as antimanic agent, 539
in bipolar depression, 558
as maintenance therapy in bipolar disorder, 573
neurotrophic and neuropotective effects, 740, 766
and signal transduction in bipolar disorder, 518

Magnetic resonance imaging
in bipolar disorder or schizophrenia in men, 147
brain anatomy in obsessive–compulsive disorder, 1210
brain changes in depression, 791
brain morphometrics in first-episode schizophrenia, 398
in depression, 813
frontal lobe in schizophrenia, 110
functional imaging in schizophrenia, 99
hippocampal volume in geriatric depression, 301
neuroimaging in bipolar disorder, 505
orbitofrontal cortex volume in geriatric depression, 971
thalamic volume in pediatric obsessive–compulsive disorder, 294
Magnetic resonance spectroscopy
basal ganglia after cocaine, 685
brain chemistry in obsessive–compulsive disorder, 1210
issues and findings in schizophrenia, 357, 369
lithium affecting *N*-acetyl-aspartate levels in brain, 1
orbitofrontal cytosolic choline levels in adolescent depression, 1053
Magnetic stimulation, transcranial
controlled trial in depression, 962
high and low frequencies affecting brain activity in depression, 1133
issues involved in, 959-ed
Magnetoencephalography
fine structure of auditory M100 in psychosis, 1109
Maintenance treatment
in bipolar disorder, 573
Mania
antimanic agents, 539
and depression. *See* Bipolar disorder
pediatric, 458
McLean–Harvard First-Episode Project
6-month outcome measures in, 467
Mecamylamine
affecting bipolar disorder in Tourette's syndrome, 1028
Melatonin
diurnal fluctuation in menstrual cycle, 1062
serum levels affected by skin light exposure, 1098
Memory
in mood disorders, 674
in schizophrenia, 99
and conditional associative learning, 406
and episodic object recognition, 651
and hippocampal volume, 1121
Menopause
and imidazoline binding sites affected by estrogen, 932
Menstrual cycle
cortisol circadian rhythms in, 920
sleep and hormonal fluctuations in, 1062

Metabolism, cerebral
and anxiety in mood disorders, 1020
regional effects of fluoxetine in depression, 830
N-Methyl-D-aspartate (NMDA)
and dopamine responses to amphetamine, 627
receptor activation
affecting neurogenesis in adults, 715, 721
and glutamatergic neurotoxicity, 755
Microdialysis samples
dopamine release in prefrontal cortex affected by ziprasidone, 229
Mirtazapine
in bipolar depression, 558
and sleep continuity in depression, 75
Mitogen-activated protein kinase
and cell survival in mood disorders, 732
and expression of bcl-2 protein, 740
Moclobemide
in bipolar depression, 558
Molecular biology
mechanisms in schizophrenia, 173
Monoamine oxidase inhibitors
in bipolar depression, 558
Mood disorders. *See* Bipolar disorder; Depression
Mood stabilizers
mecamylamine affecting bipolar disorder in Tourette's syndrome, 1028
neurotrophic effects of, 740, 766
Muscarinic receptors
in schizophrenia, 381

N200 amplitude
in Stop signal task, 238
N275 amplitude
in Go/No Go trials, 210
Naloxone
ACTH responses to, 310
National Depressive and Manic-Depressive Association
commentary on bipolar disorder, 442
National Institute of Mental Health
research goals for bipolar disorder, 436
Nefazodone
in bipolar depression, 558
Negative symptoms
in schizotaxia, 349
Neural pathways
in sadness and anxiety, 30
in schizophrenia, 81
Neurodevelopment
amygdala volumes in pediatric anxiety, 51
in schizophrenia
and bcl-2 protein expression, 641
frontal lobe abnormalities in, 110
molecular mechanisms in, 173
Neurogenesis, hippocampal
in adults, 715, 721
and cell survival in mood disorders, 732
stress affecting, 801
Neuroleptics
in bipolar depression, 558
Neuropeptides
brain levels in bipolar disorder, 486
Neuroprotection
and lithium activity, 1
Neuropsychologic function
age affecting, in schizophrenia, 137
and eyeblink conditioning in schizophrenia, 204
findings in relatives of schizophrenic patients, 120
in mood disorders, 674
Neurotoxicity
in HIV infection, steroid hormones affecting, 881
Neurotrophic factors
and effects of mood stabilizers, 740
and prefrontal cortex changes in mood disorders, 766
Neurotrophins
brain levels in bipolar disorder, 486
Neutropenia
clozapine-induced, granulocyte colony–stimulating factor levels in, 1113
Nicotinic receptor antagonist
affecting bipolar disorder in Tourette's syndrome, 1028
Nightmares
in posttraumatic stress disorder, 1081
Nizatidine
preventing olanzapine-related weight gain in schizophrenia, 166
Norepinephrine
brain levels in bipolar disorder, 486
response to cold pressor test in Alzheimer's disease, 247
transporter binding by paroxetine, 954-corr
Nortriptyline
in bipolar depression, 558

Object recognition
episodic, in schizophrenia, 651
Object retrieval
deficits from phencyclidine in monkeys, 415
Obsessive–compulsive disorder
and CSF oxytocin and vasopressin levels in eating disorders, 315
genetics and neuroimaging in, 1210
pediatric, thalamic volume in, 294
relation to other spectrum conditions, 287
Olanzapine
as antimanic agent, 539
in bipolar depression, 558
as maintenance therapy in bipolar disorder, 573
in schizophrenia, and weight gain prevention by nizatidine, 166
Opioid receptor blockade
ACTH responses to, 310
Opponent processes
and arousal in schizophrenia, 81
Oppositional defiant disorder
familial association with attention-deficit disorder, 21

Orbitofrontal cortex
abnormalities in schizophrenia, 110
cytosolic choline levels in adolescent depression, 1053
volume reduction in geriatric depression, 971
Outcome assessment
birth outcomes after fluoxetine in pregnancy, 996
effects of substance abuse in bipolar disorder, 477
6-month outcome measures in first episodes, 467
Oxcarbazepine
as antimanic agent, 539
Oxygen radicals
and hippocampal neuron loss, 755
Oxytocin
CSF levels after recovery from eating disorders, 315

P3a amplitude
in male alcoholics, 276
P300 amplitude
lateralized deficit in schizotypal personality disorder, 702
and onset of adolescent alcohol use, 265
P375 amplitude
in Go/No Go trials, 210
Panic disorder
and carbon dioxide challenge test in relatives of patients, 1223-corr
Paralimbic structures
in guilt-related imagery, 43
Paroxetine
binding to norepinephrine transporter, 954-corr
Personality disorder
schizotypal, lateralized P3 deficit in, 702
PET studies
cingulate and caudate activity in mania, 1045
in depression, 813
episodic object recognition in schizophrenia, 651
in guilt-related imagery, 43
metabolism in anxiety with mood disorders, 1020
neuroimaging in bipolar disorder, 505
pindolol augmentation of antidepressants, 844
regional cerebral blood flow affected by high and low frequencies in transcranial magnetic stimulation, 1133
regional metabolic effects of fluoxetine in depression, 830
sadness and anxiety, 30
serotonin receptors
binding affected by estradiol and progesterone, 854
in depression, 801
transgene expression, 337
Pharmacogenetics
in obsessive–compulsive disorder, 1210
Pharmacology
and molecular mechanisms in schizophrenia, 173
Phencyclidine
and object retrieval deficits in monkeys, 415
Phenelzine
in bipolar depression, 558
Phospholipid
turnover in basal ganglia affected by cocaine, 685
Phototherapy
in bipolar depression, 558
Phototransduction, extraocular
and skin light exposure affecting melatonin and bilirubin levels, 1098
Physical illness
in depressed patients, 791
Pindolol
augmentation of antidepressant treatment, 844
in bipolar depression, 558
serotonin receptor occupancy at presynaptic and postsynaptic sites, 801
Pineal gland
melatonin levels affected by skin light exposure, 1098
[^{3}H]Pirenzepine
binding muscarinic receptors in schizophrenia, 381
Polysomnography
in depression, mirtazapine affecting, 75
Postmortem studies
age affecting glial fibrillary acidic protein immunoreactivity in depression, 861
altered numbers of cells in mood disorders, 766
Posttraumatic stress disorder
comorbidity with depression, 878-ed, 902
and initial urinary cortisol levels after trauma, 940
trauma-related nightmares in, 1081
Postural sway
and onset of adolescent alcohol use, 265
Potassium
Na,K-ATPase activity in bipolar disorder, 486
Prefrontal cortex
activation in schizophrenia, 99
age affecting glial fibrillary acidic protein immunoreactivity in depression, 861
anatomy in obsessive–compulsive disorder, 1210
cell loss in mood disorders, 766
dopamine release affected by ziprasidone, 229
dysfunction from phencyclidine in monkeys, 415
and episodic object recognition in schizophrenia, 651
metabolic effects of fluoxetine in depression, 830
neuroimaging in depression, 813
responses in schizophrenia, 81
synaptophysin mRNA levels in schizophrenia, 389
transcranial magnetic stimulation in depression, 962
Pregnancy
and antidepressant concentrations in amniotic fluid, 1032
fluoxetine in, affecting birth outcomes, 996
Premenstrual dysphoric disorder
cortisol circadian rhythms in, 920
Problem solving
in mood disorders, 674
Progesterone
affecting serotonin receptor binding, 854
Protein kinase C
activity in bipolar disorder, 486
and signal transduction, 518
Psychoeducational program
in bipolar disorder, 582

Psychopathy
response inhibition in, 210
Psychotherapy
in bipolar depression, 558
interpersonal and social rhythm therapy in bipolar disorder, 593
Pulvinar region
and episodic object recognition in schizophrenia, 651
Pupillometry
time-of-day variations in, 1069

Quetiapine
as antimanic agent, 539
in bipolar depression, 558

Reboxetine
in bipolar depression, 558
Recurrence of episodes
in bipolar disorder, 445
Reporter genes
PET imaging of transgene expression, 337
Research
flexible treatment in chronic disease, 605
goals for bipolar disorder, 436
Response inhibition
in attention-deficit/hyperactivity disorder, 238
in schizophrenia or psychopathy, 210
Risperidone
as antimanic agent, 539
in bipolar depression, 558
as maintenance therapy in bipolar disorder, 573
in schizotaxia, 349
mRNA
aldolase A levels affected by lithium, 58
corticotropin-releasing hormone levels
in animal models of anxiety, 1175
and stress reactivity affected by maternal care, 1164
and synaptic protein genes in schizophrenia, 184
Rubber hand illusion
in schizophrenia, 1105

Saccades
in attentional dysfunction, 197
Sadness
neural correlates of, 30
Saliva
cortisol levels
in children, related to mother's depression, 976
depression affecting, in twins, 70
gambling affecting, 948
dehydroepiandrosterone levels in major depression, 989
Schizoaffective disorder
fine structure of auditory M100 in, 1109
Schizophrenia
adaptive life functioning in, 163
age affecting neuropsychologic function in, 137
amphetamine-induced dopamine release affected by ketamine, 627
associative learning in, 406
and cerebellar function, 204
basal ganglia activation in, 99
bcl-2 protein expression in, 641
brain morphometrics in first episode, 398
cerebellar function in, 204
cognitive function in
and reactivity to stress, 1119
and symptom severity related to cortisol levels, 1121
ECT efficacy affected by stimulus intensity, 222
emotion recognition in, 127
episodic object recognition in, 651
fine structure of auditory M100 in, 1109
magnetic resonance spectroscopy in, 357, 369
molecular mechanisms in, 173
MRI of temporal lobe structures in men, 147
muscarinic receptors in, 381
neuropsychologic deficits in relatives of schizophrenic patients, 120
olanzapine-related weight gain prevention with nizatidine, 166
parent-of-origin effect in, 706
prevention goals, 349
relation to bipolar disorder, 531
response inhibition in, 210
resting EEG abnormalities in, 1088
smooth pursuit eye movements in, 197
synaptic proteins in, 184
synaptophysin mRNA levels in, 389
touch feel illusion in, 1105
Schizotaxia
features and treatment protocols, 349
Schizotypal personality disorder
lateralized P3 deficit in, 702
Serotonin
brain levels in bipolar disorder, 486
complex (dys)function of transporter, 334-corr
depression relapse in tryptophan depletion, 327
5-HT_{1A} receptor
activation by ziprasidone, 229
knockout mice expressing fear and anxiety, 1157
5-HT_{2A} receptor binding affected by estradiol and progesterone, 854
neurotransmission in depression, 801
reuptake inhibitors
augmentation by pindolol, 84
in bipolar depression, 558
citalopram and sertraline compared, 894
comparisons of, 875-ed, 894
transporter gene polymorphism in disorders, 259, 319
Sertraline
compared to citalopram, 894
Sex chromosomes
abnormality in transsexualism, 1116
Signal transduction
in bipolar disorder, 518
calcium homeostasis affecting, 665

Skin
light exposure affecting melatonin and bilirubin levels, 1098
Sleep
architecture and obstructive apnea in depression, 1001
diurnal fluctuation in menstrual cycle, 1062
mirtazapine affecting, in depression, 75
reliability of computer analysis of EEG in, 1010
and trauma-related nightmares, 1081
Sleep deprivation
cortisol circadian rhythms in, 920
as therapy in bipolar depression, 558
thyroid function in, 323
Sleepiness
time-of-day variations in, 1069
Social rhythm therapy
in bipolar disorder, 593
Socioeconomic status
and cortisol levels in children related to mother's depression, 976
Sodium
Na,K-ATPase activity in bipolar disorder, 486
SPECT studies
ketamine affecting amphetamine-induced dopamine release, 627
neuroimaging in bipolar disorder, 505
serotonin transporter in depression, 801
Splenium
morphology in schizophrenia, 398
Stop signal task
and response inhibition in attention-deficit disorder, 238
Stress. *See also* Posttraumatic stress disorder
and adaptive plasticity in hippocampus, 721
and altered fear circuits in knockout mice, 1157
and brain changes in depression, 791
corticotropin-releasing hormone in, 1175
early events affecting brain structure and function, 778
and neurogenesis in adults, 715
neuronal activity and cell survival in, 732
prefrontal cortex cell loss in, 766
reactivity
affected by cognition in schizophrenia, 1119
affected by maternal care in infancy, 1164
serotonin receptors in, 801
Striatum
anatomy in obsessive–compulsive disorder, 1210
metabolic effects of fluoxetine in depression, 830
neuroimaging in depression, 813
Substance abuse. *See* Alcoholism; Drug abuse
Suicidal behavior
hippocampal imidazoline receptor proteins in, 910
serotonin transporter gene polymorphisms in, 259, 319
Sympathetic nervous system
response to cold pressor test in Alzheimer's disease, 247
Synaptic proteins
brain levels in bipolar disorder, 486
in schizophrenia, 184
Synaptophysin
mRNA levels in schizophrenia, 389

T cells
natural killer cells in aged depressed patients, 1024
Temperament
and anxiety symptoms, 1199
Temperature
core body rhythm in menstrual cycle, 1062
Temporal lobe
MRI of men with bipolar disorder or schizophrenia, 147
synaptic proteins in schizophrenia, 184
Thalamus
anatomy in obsessive–compulsive disorder, 1210
and episodic object recognition in schizophrenia, 651
neuroimaging in depression, 813
synaptophysin mRNA levels in schizophrenia, 389
volume in pediatric obsessive–compulsive disorder, 294
Therapeutic response
and plasma thymopoietin in depression, 65
Thymopoietin
plasma levels in depression, 65
Thyroid gland
function in sleep deprivation, 323
Thyroid hormone therapy
in bipolar depression, 558
as maintenance therapy in bipolar disorder, 573
Thyroid-stimulating hormone
diurnal fluctuation in menstrual cycle, 1062
Tiagabine
as antimanic agent, 539
Topiramate
as antimanic agent, 539
Touch feel illusion
in schizophrenia, 1105
Tourette's syndrome
and response to mecamylamine in bipolar disorder, 1028
Transsexualism
sex chromosome abnormality in, 1116
Tranylcypromine
in bipolar depression, 558
Trauma
initial urinary cortisol levels predicting posttraumatic stress disorder, 940
and pediatric mania, 458
Tricyclic antidepressants
in bipolar depression, 558
Tryptophan depletion
and risk of depression relapse, 327
Twins
depression affecting salivary cortisol levels, 70
temperament related to anxiety, 1199

Umbilical cord blood
antidepressant concentrations in, 1032
Unmedicated psychosis
and effects of subsequent treatment, 163

Valproate
as antimanic agent, 539
and expression of endoplasmic reticulum stress proteins, 658
neurotrophic and neuropotective effects, 740
Vasopressin
CSF levels after recovery from eating disorders, 315
plasma levels in depression, 330
Venlafaxine
in bipolar depression, 558
Visual event-related potentials
and onset of adolescent alcohol use, 265
and response inhibition
in attention-deficit disorder, 238
in schizophrenia or psychopathy, 210

[^{11}C]WAY-100635
in PET studies of pindolol augmentation of antidepressants, 844
Weight gain
olanzapine-associated, prevention by nizatidine, 166
Working memory
in mood disorders, 674
in schizophrenia, 99

Ziprasidone
as antimanic agent, 539
and dopamine release in prefrontal cortex, 229
Zonisamide
as antimanic agent, 539